人乳腺珠蛋白基因真核表达载体的构建及其表达

[目的]构建人乳腺珠蛋白(hMAM)基因的真核表达载体pcDNA3.1-hMAM,并观察重组载体在COS-7细胞中的表达,为肿瘤DNA疫苗研究奠定基础.[方法]利用PCR方法扩增hMAM基因,酶切测序分析后,克隆入真核表达载体pcDNA3.1,构建真核表达载体pcDNA3.1-hMAM.将重组载体用脂质体转染法转染入COS-7细胞,间接免疫荧光法检测目的基因的表达.[结果]成功扩增hMAM基因,酶切测序结果表明,重组载体含有hMAM基因,在COS-7细胞中可检测到hMAM表达.[结论]hMAM基因的真核表达载体构建成功,为进一步进行DNA肿瘤疫苗研究提供了实验依据.     

潜伏活性的人可溶性TNFⅠ型受体融合蛋白真核表达载体的构建及表达

目的:采用基因工程技术,将转化生长因子β前体相关蛋白(LAP)通过基质金属蛋白酶(MMP)水解部位与人可溶性TNFⅠ型受体(hsTNFRⅠ)连接,构建pcDNA3.1/LAP-MMP-hsTNFRⅠ融合蛋白真核表达载体,获得LAP-MMP-hsTNFRⅠ融合蛋白。方法:将编码MMP水解部位氨基酸的正反义DNA序列退火形成互补双链后定向克隆插入真核表达载体pcDNA3.1( ),得到pcDNA3.1/MMP重组体;将TGF-β1的LAP段和hsTNFRⅠ与MMP水解部位连接,获得pcDNA3.1/LAP-MMP-hsTNFRⅠ真核表达载体。测序鉴定后,脂质体介导重组质粒转染COS-7细胞,通过RT-PCR检测融合基因的表达。结果:酶切及测序结果证实pcDNA3.1/LAP-MMP-hsTNFRⅠ重组载体构建成功,转染后RT-PCR结果表明重组质粒在COS-7细胞中得到有效表达。结论:成功构建了融合蛋白真核表达载体pcDNA3.1/LAP-MMP-hsTNFRⅠ,并获得融合基因的瞬时表达,为进一步研究融合蛋白在子宫内膜异位症中的靶向治疗奠定了实验基础。     

应用基因芯片技术筛选转染NOR1基因后HepG2细胞差异表达基因

目的研究转染NOR1基因后肝癌细胞系HepG2基因表达谱的改变。方法应用脂质体介导的转染方法将pcDNA3.1( )/NOR1真核表达载体和pcDNA3.1( )空白载体分别转染入肝癌细胞系HepG2,再分别提取转染pcD-NA3.1( )/NOR1和空载体pcDNA3.1( )的HepG2细胞总RNA,应用基因芯片技术进行芯片分析。结果芯片分析结果显示差异表达基因中上调的基因有59个,下调的基因有103个,这些差异基因的功能涉及多个方面。结论应用基因芯片技术成功筛选了NOR1基因转染细胞后差异表达基因,为阐明NOR1基因与肝癌发生发展的关系提供了实验依据。     

人乳腺珠蛋白基因疫苗的构建及其免疫原性研究

目的:构建人乳腺珠蛋白(hMAM)基因重组质粒pcDNA3.1-hMAM,并观察重组质粒在COS-7细胞中的表达,为肿瘤DNA疫苗研究奠定基础。方法:利用PCR方法扩增hMAM基因,酶切测序后克隆入真核表达载体pcDNA3.1,构建真核表达载体pcDNA3.1-hMAM。将重组载体脂质体转染法转染入COS-7细胞,间接免疫荧光法和ELISA检测目的基因的表达。结果:成功扩增hMAM基因,酶切测序表明,重组质粒含有hMAM基因,在COS-7细胞中可检测到hMAM表达。结论:hMAM基因疫苗构建成功,为进一步进行DNA肿瘤疫苗研究提供了实验依据。     

端粒和端粒酶相互作用蛋白在真核细胞中的表达

目的从人肝癌细胞系HepG2中获得PinX1基因,构建真核表达载体,转染Hek293细胞。方法采用RT-PCR技术从HepG2中扩增PinX1,克隆入真核表达载体pcDNA3,重组质粒转染Hek293细胞,免疫组化法检测蛋白的表达。结果RT-PCR方法扩增获得PinX1基因,构建真核表达载体pcDNA3-PinXl-vsv重组质粒转染Hek293细胞,免疫组化检测结果表明在细胞核内有PinX1表达。结论成功获得PinX1基因,构建的重组载体可在Hek293细胞内表达,为探索PinX1在端粒、端粒酶调控中的作用机制奠定基础。     

过表达GCNF对HeLa细胞生物学行为的影响

目的:将成功构建的人pcDNA3.1-GCNF真核表达载体瞬时转染宫颈癌HeLa细胞,观察GCNF基因对HeLa细胞生物学功能的影响。方法:将重组质粒pcDNA3.1-GCNF转染HeLa细胞,通过MTT比色法、基质胶黏附实验和Transwell侵袭试验对转染后HeLa细胞增殖、黏附和侵袭力进行分析。结果:成功获得瞬时转染的pcDNA3.1-GCNF HeLa细胞,转染目的基因组(0.239±0.014)与转染空质粒组(0.198±0.020)及未转染组(0.204±0.012)相比,细胞增殖最快(P<0.05)。转染目的基因后细胞粘附、侵袭力未见明显改变。结论:GCNF基因促进了体外培养的宫颈癌HeLa细胞增殖,但对HeLa细胞粘附、侵袭力没有明显的影响。     

全长型人Smac基因真核表达载体构建及表达

目的 构建全长型(full length,FL)人Smac基因(hSmac)真核表达载体pcDNA3.1 -FL hSmac,并在肝癌细胞中表达.方法 应用逆转录聚合酶链式反应(RT-PCR)技术从人宫颈癌细胞株Hela中扩增到Smac CDs基因片段,构建重组真核表达载体peDNA3.1 -FL hSmae.PCR、酶切鉴定重组质粒正确后,通过脂质体介导将其和作为阴性对照的空载体pcDNA3.1 分别转染人肝癌细胞株(SMMC-7721).同时转染含EGFP的质粒pcDNA3.1 -EGFP.利用荧光显微镜和流式细胞术检测转染效率.采用RT-PCR、western blot法检测外源基因Smac的表达.结果 PCR扩增片段与预期片段大小相符,插入片段测序结果与GenBank公布的一致,表明人Smac基因克隆成功.且鉴定证实真核表达载体pcDNA3.1 -FL hSmac构建成功.流式细胞术检测到转染效率高达48%,荧光显微镜下也可见非常明亮的绿色荧光.无论是在mRNA水平还是蛋白水平上,转染后的细胞中外源基因Smac表达均明显增加.结论 成功构建重组真核表达载体pcDNA3.1 -FL hSmac,并在肝癌细胞中明显表达,为研究Smac基因在细胞凋亡过程中的调控作用.以及探讨以Smac基因为基础的肿瘤基因治疗策略提代基础依据.     

FAT10过表达对肝癌细胞HepG2侵袭及迁移能力的影响

目的 探讨FAT10过表达对肝癌细胞HepG2侵袭及迁移的影响.方法 采用脂质体转染法建立FAT10基因过表达的HepG2细胞株;采用蛋白质印迹法检测转染重组表达载体pcDNA3-FAT10后,HepG2细胞中FAT10蛋白的表达水平.体外侵袭实验及划痕实验检测FAT10基因过表达对HepG2细胞迁移及侵袭能力的改变,并采用芯片检测FAT10下游与细胞侵袭转移相关基因的差异表达.结果 蛋白质印迹法检测结果显示,转染重组表达载体pcDNA3.1-FAT10的HepG2细胞中FAT10蛋白均过表达;FAT10过表达能明显提高HepG2细胞的侵袭及迁移能力.结论 FAT10基因在HepG2细胞中过表达能提高肝癌的侵袭及迁移能力,并促进肝癌的发生及发展.     

hMAM与人HSP70融合基因真核表达载体的构建与表达

目的:构建人乳腺珠蛋白(hMAM)与人热休克蛋白70(hHSP70)融合基因的真核表达载体pcDNA3.1-hMAM-HSP70,并观察重组载体在COS-7细胞中的表达,为肿瘤DNA疫苗研究奠定基础。方法:利用PCR方法扩增hMAM基因,经酶切测序分析后,与人HSP70基因克隆入真核表达载体pcDNA3.1,构建了融合基因真核表达载体pcDNA3.1-hMAM-HSP70。将重组载体电穿孔法转染入COS-7细胞,间接免疫荧光法检测目的基因的表达。结果:成功扩增了人HSP70基因与hMAM基因,酶切测序结果表明,重组载体含有hMAM与人HSP70的融合基因,在COS-7细胞中可检测到hMAM表达。结论:hMAM与人HSP70融合基因的真核表达载体构建成功,为进一步进行DNA肿瘤疫苗研究提供了实验依据。     

奈瑟氏淋球菌外膜蛋白PIA基因的克隆、真核表达与鉴定

目的克隆奈瑟氏淋球菌外膜蛋白PIA基因,构建稳定的真核重组表达载体,并在HELA细胞中表达。方法根据淋球菌PIA基因序列,利用Primer Premier5.0生物学软件设计一对特异性扩增引物,以淋球菌国际标准株基因组DNA为模板,PCR扩增除掉信号肽后PIA基因开放读码框（ORF）,将其插入真核表达载体pcDNA3.1（＋）,构建含目的基因的pcDNA3.1（＋）/PIA重组质粒,PCR及酶切鉴定重组载体,脂质体转染HELA细胞,以间接免疫荧光法检测PIA基因在HELA细胞中的表达。结果成功构建了pcDNA3.1（＋）/PIA重组质粒;pcDNA3.1（＋）/PIA能在HELA细胞中高效表达PIA蛋白。结论重组质粒pcDNA3.1（＋）/PIA构建成功并在HELA细胞中高效表达了PIA蛋白,为该蛋白的抗原性及功能学研究奠定了基础。     

缬沙坦/氨氯地平和依贝沙坦/双氢克尿噻联合治疗老龄高血压疗效的研究

Objective To compare the clinical effect of valsartan/amlodipine combination or irbesartan/hydrochlorothiazide(HCTZ)combination in very elderly hypertensives.Methods After a 4-week placebo period,94 hypertensives,aged 75-89 years were random given valsartan 160 mg/amlodipine 5 mg or irbesartan 300 mg/HCTZ 12.5 mg for 24 weeks according to a rospective study.After 4 weeks,amlodipine or HCTZ was doubled in non-responders.Patients were checked every 4 weeks.At each visit,sitting,lying and standing blood pressure(BP),systolic BP(SBP)and diastolic BP(DBP)were measured. At the end of placebo period and treatment period,electrolytes and uric acid were evaluated.Results Blood pressure was significantly decreased in both treatment groups,however,there was no statistical significance between two groups.BP changes from lying to standing position were significantly greater in the irbosartan/HCTZ group(-17.2/-9.1 mmHg)than that in the valsartan/amlodipine group(-10.1/-1.9 mmHg,t=2.14,P＜0.05 for SBP and t=3.11,P＜0.01 for DBP vs.irbesartan/HCTZ).Potassium significantly decreased and uric acid significantly increased(-0.4 mmol/L,t = 2.33,P＜ 0.05 and+29.7μ mol/L,t =2.54,P＜0.05 vs.baseline,respectively)only in the irbesartan/HCTZ group.Conclusions Both combinations had similarly effective in reducing clinical BP in very elderly hypertensives.However,valsartan/amlodipine offered some advantage and less pronounced BP orthostatic changes and absence of metabolic adverse effects.     

乙酰半胱氨酸对肥胖哮喘小鼠气道炎症和重建的作用

目的探讨乙酰半胱氨酸对哮喘气道炎症和重建的影响。方法60只雌性C57／6J小鼠按随机数字表法分为哮喘组（A组）,肥胖哮喘组（B组）,治疗组（C组）,对照组（D组）,每组15只。经腹腔注射与雾化吸入卵蛋白（OVA）制作慢性哮喘模型,高脂饮食制造肥胖模型。计数支气管肺泡灌洗液（BALF）中细胞总数及分类,ELISA法测定肺组织匀浆中IL-6和8-异前列腺素F2α（8-iso-PGF2α）水平,肺组织切片观察各组小鼠病理变化,并测定气管壁面积（WAt）、气管平滑肌面积（WAm）、管腔基底膜周长（Pbm）。结果,A组、B组小鼠BALF中白细胞总数及嗜酸性粒细胞比例、肺组织IL-6水以及病理切片中气管壁厚度（WAt／Pbm）、气管平滑肌厚度（WAm／Pbm）均较D组明显增加,且B组IL-6和WAt／Pbm较A组进一步增加（P〈0．05）。C组小鼠BALF中白细胞总数、IL-6和WAt／Pbm均较B组明显下降（P〈0．05）。四组小鼠肺组织匀浆8-iso—PGF2α水平按D组、C组、A组、B组依次升高,各组差异有统计学意义（F=101．8,P〈0．01）。Pearson相关分析表明,8-iso—PGF2α水平与肺组织IL-6水平和WAt／Pbm和呈正相关（r=0．817、0．737,P〈0．01）。结论乙酰半胱氨酸能够通过抑制氧化应激反应,抑制哮喘小鼠的气道炎症和气道重建。     

脂多糖对人皮肤成纤维细胞胶原代谢的影响

目的探讨脂多糖（1ipopolysaccharide,LPS）对人皮肤成纤维细胞胶原代谢的影响,以了解LPS在增生性瘢痕形成中的生物学作用。方法取正常皮肤行成纤维细胞培养后,分为1个对照组及6个实验组。实验组分别与终浓度为0．005、0．010、0．050、0．100、0．500和1．000μg／ml大肠杆菌LPS（Ecoli055：B5）培养,对照组DMEM培养。用逆转录-聚合酶链反应（RT-PCR）法测定成纤维细胞Ⅰ、Ⅲ型前胶原mRNA及胶原酶mRNA的表达,并以同一个体相同代数的瘢痕组织成纤维细胞做对照。结果与对照组比较,LPS刺激浓度在0．005-0．1μg／ml时,促进正常皮肤成纤维细胞Ⅰ、Ⅲ型前胶原mRNA表达（0．323±0．041,0．303±0．063,0．391±0．071,0．344±0．086,0．488±0．059,0．401±0．087,0．616±0．107,0．434±0．084,0．823±0．092,0．542±0．082）,抑制胶原酶mR-NA表达（0．598±0．068,0．556±0．049,0．441±0．043,0．372±0．083,0．260±0．027）,且呈一定的剂量依赖性;当LPS刺激浓度为0．5μ／ml,上述作用下降（0．451±0．063,0．374±0．072,0．360±0．062）;而当LPS刺激浓度到达1．0μg/ml时,抑制正常皮肤成纤维细胞Ⅰ、Ⅲ型前胶原mRNA表达（0．162±0．025,0．171±0．061）,促进胶原酶mRNA表达（0．444±0．114）。LPS刺激浓度在0．1μg／ml时,成纤维细胞（0．823±0．092,0．542±0．082,0．260±0．027）Ⅰ、Ⅲ型前胶原mRNA和胶原酶mRNA表达与同一个体增生性瘢痕组织成纤维细胞（0．829±0．049,0．569±0．038,0．277±0．059）近似。结论LPS对人皮肤成纤维细胞Ⅰ、Ⅲ型前胶原mRNA和胶原酶mRNA的表达,其直接调节可能是参与增生性瘢痕形成的重要机制。     

异丙酚对大鼠肺缺血/再灌注损伤的保护作用

Objective To study the protective effects of propofol against ischemia/reperfusion injury in rat lung. Methods Rat model of pulmonary ischemia/reperfusion injury was used in this study. Rats were randomly divided into three groups, including sham opera-tion group (group A), iachemia/reperfusion group (group B) and propofol group (group C), 15 rats in each group. The concentration of tumor necrosis factor -α and interleukin-6 in bronchoalveolar lavage fluid (BALF) were measured by enzyme linked immunosorbent assay (ELISA). Then blood gas analysis, lung wet/dry (W/D) weight ratio were detected in each group. Results Propofol could significantly improve PaO2, reduce the W/D value and the contents of TNF-α and IL-6 in BALF. Conclusion Propofol effectively suppressed the pro-duction and release of inflammatory cytokine, therefore it can protect the lung from isehemia/reperfusion injury.     

降钙素对大白兔糖尿病骨质疏松模型假体骨密度及生物力学的影响

Objective To investigate the influence of calcitonin on bone mineral density and biomechanics around the artificial pros-thesis in ovariectomized diabetic rabbit model. Methods Fourteen femina New Zealand white rabbits at the age of 5 months old were select-ed, which weight 2.24 -2.65kg, averaging 2.26kg. First, the model of rabbit with diabetic osteoporosis was successfully established by the compound method of ovariectomy plus streptozotocin. Osteotomy in the middle part of femur was performed in both groups, fixation of artifi-cial prosthesis was done with 3.0 kirschner wire. After that, Rabbit models with diabetic osteoporosis were randomly divided into experimen-tal group and control group. Rabbits in the experimental group were treated with calcitonin 6U intramuscular injection once every other day. In control group, intramuscular injection of normal saline solution 1.5ml once every three days. Rabbit models of two groups were sacrificed in the 24th week. The BMD of the region of interest (ROI) around the prosthesis were detected before experiment and 8, 16 and 24 weeks after injection. After rabbits were killed, experimental femurs in both groups were complete removal and soft tissues were rejected. Determi-nation of the pull-out and torsion bone biomechanics experiments of prosthesis was done in both groups respectively. Results The BMD of ROI in the experimental group before operation was (0.1863±0.004)g/cm2 and (0.1753±0.005)g/cm2 in 24 weeks after operation, in control group before operation was (0.1865±0.002)g/cm2 and (0.1638±0.005)g/cm2 in 24 weeks after operation. There were significant difference between the two groups(P < 0.05). Biomechanical show that the pull-out strength in the experimental group was (312.68±8.73 )N/cm2 and (205.43±12.45 ) N/cm2 in control group. There were significant difference between the two groups(P < 0.05). The tor-sion strength in experimental group was (80.47±2.51) N/cm2 and (38.52±0.64) N/cm2 in control group. There were significant differ-ence between the two groups(P < 0.05). Conclusion Salmon calcitonin can reduce the bone turnover rate around prosthesis and decrease bone absorption in the rabbit of diabetic osteoporosis models, accelerate the bone formation around prosthesis, and increase the BMD. It can ameliorate the quality of bone around prosthesis, improve its biomechanics property, and increase the holding power between prosthesis and body mass. It is of clinical significance for the prevention and treatment of aseptic loosening artificial prosthesis.     

强直性脊柱炎合并骨质疏松的临床研究

Objective To investigate the incidence of osteoporosis (OP) in patients with ankylosing spondylitis and the relationship between OP and the clinical data. Methods Serum levels of bone alkaline phosphatase (BALP) and tartrate resistant acid phosphatase 5b (TRACP5b) were detected by enzyme linked immunosorbent assay ( ELISA ) in 60 cases with ankylosing spondylitis, and it was compared with normal controls. Bone mineral density (BMD) was measured through dual-energy X-ray absorptiometry ( DXA), including lumbar ( L2 - L4), bilateral femoral neck and greater trochanter. Some clinical data was collected and analyzed at the same time. Results The incidence of OP in AS patients was 35%, and the incidence of OP in the femoral proximal end was higher than that in lumbar. Compared with normal controls[ ( 1.06 ±0. 18 )U/L ], the levels of serum TRACP5b in AS[ (1.31 ± 0. 82 )U/L] patients was significantly higher ( P <0. 05 ). The levels of serum BLAP in OP combined AS group[ ( 21.65 ± 5.41 ) U/L]were significantly lower than non-OP group[ (32. 37 ± 16. 5 ) U/L] ( P <0. 05 ). The disease duration was negatively correlated with the BMD of femoral neck ( P < 0. 01 ). Conclusions There was higher incidence of OP in AS patients, which were related with the abnormality of bone metabolism and the disease duration.Multiple factors participated in the regulation of bone metabolism of AS.     

蝶鞍结构与垂体瘤生长方式关系的影像学研究

目的 从影像学角度探讨蝶鞍相关解剖对垂体腺瘤生长方式的潜在影响.方法 按照常用蝶窦分类方法,共收集83例蝶窦气化类型为全鞍型和20例鞍前型正常头颅的影像学资料;同时收集45例影像学提示为侵入蝶窦生长的垂体腺瘤临床资料进行分析.结果 （1）正常鞍底形态与蝶窦气化程度的关系：全鞍型蝶窦更易导致凹陷型鞍底（98.8%）.（2）正常鞍底形态与垂体上缘形态的关系：凹陷型垂体上缘更易伴随凹陷型鞍底（93.8%）.（3）根据正常头颅正中矢状位鞍窝骨性上口前后径与鞍窝前后最大径之间的关系,对蝶鞍形态提出初步分型：囊袋型、炒锅型、直筒型及筛型.（4）所有向蝶窦生长的垂体腺瘤患者蝶窦均为全鞍型.结论 鞍底形态、蝶窦气化程度及蝶鞍形态等综合因素能够解释垂体腺瘤向鞍底蝶窦生长的现象;结合文献,蝶鞍的相关形态学基础应该是影响垂体腺瘤生长方式的主要因素.     

关节腔内注射洛伐他汀预防骨关节炎软骨退变

目的 研究洛伐他汀关节腔内注射对骨关节炎(OA)模型关节软骨退变及对基质金属蛋白酶(matrix metalloprotein-ase-1,3)mRNA表达的影响.方法 30只6个月龄新西兰大白兔行右膝关节前交叉韧带切断术.手术后将动物随机分为实验组和对照组,实验组术后立即给予关节腔内注射0.5 mg/ml洛伐他汀0.2 ml/kg,每周1次,连续6周;对照组则关节腔内注射等容量的生理盐水.术后6周处死动物.在解剖镜下观察股骨内髁关节软骨的大体形态学改变并评分.用反转录-聚合酶链式反应检测软骨及滑膜中MMP-1,3 mRNA的表达.结果 解剖镜下实验组软骨退变程度较对照组明显减轻;实验组关节液中IL-1水平较对照组明显降低;实验组滑膜中MMP-1,3 mRNA的表达水平显著低于对照组(P<0.05),而软骨中的MMP-1,3 mRNA的表达较对照组差异无统计学意义(P>0.05).结论 在OA早期关节腔内注射L洛伐他汀能够明显降低MMP-1,3 mRNA的表达,减轻骨关节炎软骨的退变.     

利尿剂在三聚氰胺及三聚氰酸致大鼠急性肾损伤中的治疗作用

Objective To investigate the effect of diuretic (furosemide) therapy on kidney injury induced by melamine and cyanuric acid in rats. Methods 36 male Spragne Dawley rats were random disided into 3 groups. Group A was treated with 2mL of water daily, group B was treated with melamine and cyanuric acid ( each 100 mg/kg) daily for 4 days and then 2ml of water daily, group C was treated with the same as group B at the first 4 days and then treatment with furosemide (20mg/kg) daily. Samples of blood and 24h urine were collected to detective biochemical indexes, and kidney sections were performed on days 4 and 11 ( each end point, n = 6). The kidneys were observed with histopathology and renal crystal deposition scores were determined. Results On the 4th day, group B and group C were resulted in acute kidney injury such as oliguria [ ( 3. 39 ± 1.02 ) ml, ( 3. 20 ± 0. 86 ) ml ] and high serum creatinine [ ( 153.54 ±27. 08)μmol/L, (160. 11 ± 19. 55)μmol/L] and renal melamine cyanurate crystal were found in the renal tissues. On the 11th day, the renal crystal deposition score in the rats was reduced by 9. 52% ( P >0. 05). Compared with those of the 4th day in group B, it reduced by 63.63%( P <0.05) in group C. Urine volume were increased significantly compared with those of the 4th day( P < 0. 05 ) in group C [ from (3.20±0. 86)ml to (25.96 ±5.97)ml] and group B [ from(3. 39 ± 1.02)ml to (8. 57 ± 1.66)ml] , and Urine volume in group C was increased significantly more than that in group B ( P < 0. 05 ). The serum creatinine was obviously reduced as compared with those of the 4th day in group B and C( P <0.05), from[ (153. 54±27.08) μmol/L] to [ ( 106. 10 ±5.53) μmol/L] in group B and from [ ( 160. 11 ± 19. 55) μmol/L] to [ (67. 17 ± 12. 80 ) μmol/L] in group C, but the serum creatinine in group B was still higher than that in group A and C ( P < 0. 05). Conclusions Furosemide can attenuate the damage of acute kidney injury induced by melamine and cyanuric acid.     

脓毒症血清对大鼠小肠微血管内皮细胞ICAM-1的影响及肾上腺髓质素的干预作用

Objective To observe the levels of intercellar adhesion molecule-1(ICAM-1)of rat intestinal mucosa microvascular endothelial cells in sepsis rat,and to investigate the possible protective effect of adrenomedullin on the expression of intercellar adhesion molecule-1(ICAM-1)of rat intestinal mucosa microvascular endothelial cells,and to confirm whether adrenomedullin can decrease released inflammatory factors to slow down or inhibit the occurrence and development of sepsis.Methods The rat intestinal mucosa microvascular endothelial cells were isolated and cultured in vitro,and it was divided into sham operated(sham operated serum),sepsis serum(with addition of sepsis serum)and ADM serum(with 0.lng/kg adrenomedullin 6h after sepsis treatment)groups.The soluble ICAM-1(sICAM-1)content in RIMMVECs culture supernatant was measured by ELISA at the 24th hour after serum stimulation.Results The ICAM-1 content in the supernatant of sepsis group [(0.33 ±0.04)ng/L] was obviously higher than that in sham operated [(0.15 ± 0.02)ng/L] and ADM [(0.17 ± 0.04)ng/L] group(P ＜ 0.05),but ADM group was no significantly different compared with sham operated group(P ＞ 0.05).Conclusions ADM could decrease the expression of ICAM-I in RIMMVECs,and the low level of ICAM-1 could suppress its downstream inflammation factors and inhibit the occurrence and development of sepsis.